FY2028 Earnings Forecast for Aptevo Therapeutics Inc. Issued By Roth Capital (NASDAQ:APVO)

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Roth Capital issued their FY2028 EPS estimates for shares of Aptevo Therapeutics in a note issued to investors on Friday, April 19th. Roth Capital analyst J. Aschoff expects that the biotechnology company will earn $2.76 per share for the year. The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($57.83) per share.

Separately, StockNews.com began coverage on Aptevo Therapeutics in a research report on Thursday. They issued a “sell” rating for the company.

Aptevo Therapeutics Trading Down 5.5 %

Aptevo Therapeutics stock opened at $0.73 on Monday. The stock has a 50-day simple moving average of $4.67 and a 200 day simple moving average of $7.65. Aptevo Therapeutics has a 52 week low of $0.70 and a 52 week high of $91.96.

Hedge Funds Weigh In On Aptevo Therapeutics

Several large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP acquired a new position in Aptevo Therapeutics in the 4th quarter valued at about $29,000. Virtu Financial LLC bought a new stake in shares of Aptevo Therapeutics during the second quarter worth approximately $46,000. Citadel Advisors LLC acquired a new position in shares of Aptevo Therapeutics in the fourth quarter valued at approximately $47,000. Renaissance Technologies LLC grew its position in shares of Aptevo Therapeutics by 45.8% in the second quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 25,200 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Aptevo Therapeutics during the first quarter worth approximately $152,000. 8.06% of the stock is owned by institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.